Altan Pharma lanceert linezolideoplossing (2 mg/ml) voor infuus in Spanje
DUBLIN & MADRID–(BUSINESS WIRE)– Altan Pharma Limited, een gespecialiseerd Iers farmaceutisch bedrijf, heeft vandaag bekendgemaakt dat het zijn linezolideoplossing (2 milligram/ milliliter) voor de behandeling van buiten het ziekenhuis opgelopen longontstekingen en nosocomiale longontstekingen in Spanje lanceert via zijn Spaanse dochteronderneming Genéricos Españoles Laboratorio, S.A.U.
Volgens IMS had de Spaanse markt voor infusen met linezolideoplossingen in 2015 een waarde van 23 miljoen euro.
|
Altan Pharma Announces the Launch of Linezolid 2mg/ml Solution for Infusion in Spain
|
|||||
|
DUBLIN & MADRID–(BUSINESS WIRE)– Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company today announced that it has launched linezolid 2mg/ml solution for infusion for the treatment of community acquired pneumonia and nosocomial pneumonia in Spain through its Spanish subsidiary Genéricos Españoles Laboratorio, S.A.U. According to IMS, the market for Linezolid solution for infusion in Spain was roughly €23 million in 2015. About Linezolid Solution for Infusion Linezolid is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. It is also indicated for the treatment of complicated skin and soft tissue infections only when microbiological testing has established that the infection is known to be caused by susceptible Gram positive bacteria. Linezolid should only be initiated in a hospital setting. Please see the package insert for indications, complete side effect profile and prescribing information. About Altan Pharma Ltd. Altan Pharma Ltd. is a privately held, specialty pharmaceutical company that develops, manufactures and commercialises injectable drugs for the hospital and other provider segments. Altan has an international distribution network covering many European, Latin American and Asian markets. The company is highly focused on building its pipeline of injectable drugs and expanding its commercial presence to new markets through both organic and inorganic means. For more information visit www.altanpharma.com View source version on businesswire.com: http://www.businesswire.com/news/home/20160303005871/en/ Contacts Altan Media Relations |
|||||